Munich Cancer Registry



- ▶ Baseline statistics
- ▶ Selection Matrix
- ▶ Homepage
- ▶ Deutsch

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

C15-C26: GI cancer

Year of diagnosis	1988-2012
Patients	89,035
Diseases	91,919
Cases evaluated	49,795
Creation date	03/25/2014
Export date	02/12/2014
Population	4.5 m



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C1526E.pdf




Figure 1a. Relative survival of patients with GI cancer by period of diagnosis. Included in the evaluation are 49,795 cases diagnosed between 1988 and 2012.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1988, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis 1988-1997 1998-					
	1988-	1997	199	+8		
	n=13	,150	n=36	,645		
Years	obs. %	rel. %	obs. %	rel. %		
0	100.0	100.0	100.0	100.0		
1	73.0	75.7	67.7	70.2		
2	60.6	65.0	55.5	59.4		
3	53.2	59.0	48.5	53.7		
4	47.9	55.0	43.9	50.2		
5	44.0	52.2	40.1	47.3		
6	40.6	49.9	37.1	45.3		
7	37.8	47.9	34.5	43.6		
8	35.1	46.1	32.5	42.4		
9	33.2	45.1	30.5	41.2		
10	31.4	44.2	28.9	40.4		
11	29.7	43.2	27.4	39.6		
12	27.7	41.9	26.1	39.2		
13	25.9	40.5	24.6	38.4		
14	24.1	39.1	22.9	37.1		
15	22.8	38.3				
16	21.5	37.4				
17	20.5	36.9				
18	19.3	36.1				
19	18.0	35.0				
20	16.6	33.7				

Table 1b. Observed (obs.) and relative (rel.) survival of patients with GI cancer by period of diagnosis for period 1988-2012 (N=49,795).




Figure 2a. Survival of patients with GI cancer by gender. Included in the evaluation are 49,795 cases diagnosed between 1988 and 2012.

Gender								
	Ma	ale	Fem	nale				
	n=27	,192	n=22	,603				
Years	obs. %	rel. %	obs. %	rel. %				
0	100.0	100.0	100.0	100.0				
1	69.0	71.6	69.2	71.8				
2	56.3	60.4	57.5	61.6				
3	48.8	54.2	50.9	56.2				
4	43.9	50.5	46.2	52.7				
5	40.0	47.6	42.5	50.0				
6	36.7	45.2	39.6	48.1				
7	34.0	43.4	37.0	46.3				
8	31.7	41.9	34.8	45.0				
9	29.7	40.7	32.9	44.1				
10	28.0	39.8	31.2	43.2				
11	26.5	39.0	29.6	42.3				
12	24.8	38.0	27.9	41.2				
13	23.2	36.8	26.2	40.1				
14	21.5	35.5	24.5	38.8				
15	20.1	34.6	23.3	38.2				
16	19.1	34.0	21.9	37.2				
17	18.3	33.6	20.9	36.6				
18	17.0	32.8	19.8	36.0				
19	15.8	31.8	18.5	34.8				
20	14.7	31.1	17.0	33.1				

Table 2b. Observed (obs.) and relative (rel.) survival of patients with GI cancer by gender for period 1988-2012 (N=49,795).




Figure 3a. Relative survival of patients with GI cancer by age category. Included in the evaluation are 49,795 cases diagnosed between 1988 and 2012.




Figure 3b. Observed survival of patients with GI cancer by age category. Included in the evaluation are 49,795 cases diagnosed between 1988 and 2012.

	Age category												
	0-49	yrs	50-59	9 yrs	60-69	9 yrs	70-79	9 yrs	80+	yrs			
	n=3,	613	n=8,	196	n=14	,251	n=14,501		n=9,234				
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %			
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0			
1	79.7	79.9	76.9	77.4	73.9	75.0	66.8	69.4	54.1	60.6			
2	67.2	67.5	64.3	65.2	62.3	64.3	54.8	59.2	40.9	51.4			
3	60.5	60.9	57.5	58.7	55.4	58.2	47.8	53.9	32.9	46.7			
4	57.4	58.0	53.1	54.7	50.7	54.3	42.5	50.3	27.6	44.6			
5	54.1	54.8	49.8	51.8	47.2	51.5	38.4	47.9	23.2	42.8			
6	51.4	52.2	47.4	49.7	44.1	49.2	35.0	46.3	19.4	41.8			
7	49.1	50.1	45.1	47.8	41.7	47.6	32.2	45.2	16.2	40.9			
8	47.6	48.8	43.7	46.8	39.7	46.5	29.1	43.7	13.4	40.0			
9	46.9	48.2	42.5	46.1	37.8	45.6	26.6	42.9	10.9	39.6			
10	45.7	47.3	41.3	45.3	36.6	45.3	24.2	42.4	8.9	39.2			
11	44.8	46.5	40.1	44.6	35.2	45.2	22.1	42.2					
12	43.7	45.7	39.0	44.0	33.5	44.7	19.8	41.6					
13	42.6	44.7	37.9	43.4	31.7	44.0	17.5	40.7					
14	41.4	43.7	36.6	42.6	29.8	43.2	15.2	39.8					
15	40.8	43.4	35.5	42.2	28.2	42.9	13.5	39.7					
16	40.5	43.4	34.7	41.9	26.7	42.3	11.5	38.7					
17	39.9	43.0	34.0	41.8	25.4	42.3	9.9	38.0					
18	39.5	42.9	33.3	41.8	23.4	42.0	8.4	38.0					
19	38.9	42.8	32.6	41.8	21.3	40.9							
20	38.5	42.7	31.5	41.8	18.9	39.4							

Table 3c. Observed (obs.) and relative (rel.) survival of patients with GI cancer by age category for period 1988-2012 (N=49,795).




Figure 4a. Relative survival of patients with GI cancer by ICD-10 classification. Included in the evaluation are 49,795 cases diagnosed between 1988 and 2012.

	ICD-10 classification													
							C19							
	C15 Oes	ophagus	C16 St	omach	C17 Small intestine		C18 Colon		Rectosigmoid		C20 Rectum		C21 Anus, anal canal	
	n=2.224 n=7.7		700		200	- 40	704	junc						
	n=2,	224	n=7,	760	n=6	069	n=18	,701	n=1,	999	n=9,	,321	n=8	323
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	47.7	48.9	57.8	60.3	83.8	85.9	80.0	83.4	84.7	87.4	84.2	87.0	86.5	89.0
2	29.3	30.6	43.9	47.5	76.1	79.6	69.7	75.4	75.0	79.8	73.2	78.0	76.2	80.5
3	22.8	24.4	36.9	41.3	70.8	75.6	62.7	70.3	67.3	73.7	65.2	71.5	68.3	73.9
4	19.3	21.1	33.0	38.2	66.5	72.4	57.4	66.8	60.7	68.5	59.2	66.8	62.7	69.3
5	16.7	18.6	30.0	35.9	61.9	68.9	53.2	64.2	55.5	64.8	53.9	62.7	59.4	67.1
6	15.2	17.3	28.0	34.6	57.8	65.6	49.5	62.1	51.4	61.8	49.3	59.0	55.8	64.4
7	13.9	16.2	25.7	33.0	54.5	63.0	46.1	60.1	47.2	58.7	46.1	56.9	52.4	62.1
8	12.5	14.9	24.0	31.8	50.7	59.8	43.0	58.3	43.5	56.0	43.5	55.3	50.9	61.3
9	11.4	13.9	22.3	30.6	47.4	57.3	40.7	57.3	41.1	54.4	41.2	54.0	47.7	58.8
10	10.8	13.5	21.3	30.1	45.4	56.1	38.5	56.4	38.6	53.1	39.0	52.9	44.2	56.1

			IC	CD-10	classif	ication	า				
cont'd	C22	Liver	C23 Gal	lbladder	C24 Bilia	ary tract	C25 Pancreas C26 Digestive organs				
	n=2,	,249	n=6	657	n=1,	096	n=4,	543	n=86		
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	41.6	42.7	37.6	39.3	53.4	55.3	33.7	34.7	26.5	27.2	
2	27.2	28.7	24.1	26.1	34.9	37.2	16.8	17.6	20.2	20.4	
3	19.5	21.0	18.3	20.6	25.5	27.8	11.4	12.2			
4	15.2	16.8	16.3	18.9	21.2	23.8	8.7	9.6			
5	12.2	13.7	14.5	17.3	18.5	21.1	7.1	8.0			
6	10.1	11.6	13.0	16.1	17.5	20.4	6.3	7.2			
7	9.3	10.9	11.8	15.1	14.9	17.9	5.7	6.7			
8	8.5	10.1	10.0	13.5	13.8	16.9	5.1	6.2			
9	7.8	9.5	9.6	13.4	12.4	15.6	4.7	5.8			
10	7.1	8.8	8.3	12.1	11.3	14.7	4.4	5.6			

Table 4b. Observed (obs.) and relative (rel.) survival of patients with GI cancer by ICD-10 classification for period 1988-2012 (N=49,795).






Figure 4c. Relative survival of patients with GI cancer by ICD-10 classification. Included in the evaluation are 36,645 cases diagnosed between 1998 and 2012.

					IC	CD-10	classif	icatio	n						
									C1	9					
	C15 Oes	ophagus	C16 St	omach	C17 Small intestine		C18 (C18 Colon		Rectosigmoid		C20 Rectum		C21 Anus, anal canal	
									junc	tion					
	n=1,	723	n=5,	570	n=5	60	n=13	,438	n=1,	530	n=6,	065	n=606		
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	47.6	48.8	56.2	58.9	85.3	87.2	79.6	83.0	84.9	87.7	83.8	86.6	85.8	88.1	
2	29.0	30.3	42.3	45.8	77.6	80.9	69.6	75.3	75.2	79.9	73.3	78.0	77.4	81.5	
3	22.6	24.1	35.3	39.5	72.4	77.0	62.7	70.3	68.0	74.4	65.5	71.7	69.8	75.1	
4	19.3	21.0	31.3	36.3	67.6	73.2	57.7	67.1	61.5	69.3	59.6	67.2	64.8	71.2	
5	16.9	18.8	28.3	34.0	63.4	70.2	53.1	64.1	56.3	65.5	54.8	63.4	61.5	69.1	
6	15.3	17.4	26.6	33.1	58.0	65.4	49.3	61.8	51.9	62.2	50.5	60.1	58.4	66.8	
7	13.5	15.7	24.2	31.2	54.4	62.3	46.0	59.9	48.0	59.2	47.9	58.7	55.1	64.7	
8	12.4	14.6	22.8	30.5	50.6	59.4	43.3	58.6	44.1	56.3	45.4	57.2	54.2	64.4	
9	11.0	13.2	20.8	28.8	49.2	58.4	40.8	57.3	41.8	54.8	43.2	56.1	49.7	60.5	
10	10.2	12.6	19.8	28.1	48.3	58.4	38.5	56.3	38.8	52.9	41.0	55.2	45.2	55.8	

			IC	CD-10	classif	icatio	า				
cont'd	C22	Liver	C23 Gal	lbladder	C24 Bilia	ary tract	C25 Pa	ncreas	C26 Digestive organs		
	n=1,	907	n=4	198	n=8	372	n=3,	798	n=	78	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	40.9	42.1	36.2	37.7	51.7	53.6	34.3	35.3	22.7	23.2	
2	26.9	28.3	21.2	23.0	32.7	34.9	17.0	17.8			
3	19.2	20.7	16.8	18.9	22.9	24.9	11.3	12.1			
4	15.4	17.0	15.1	17.3	18.6	20.8	8.5	9.3			
5	12.0	13.6	13.5	15.7	16.0	18.3	6.9	7.7			
6	10.3	11.7	11.6	14.2	14.8	17.1	5.9	6.8			
7	9.1	10.7	9.9	12.1	11.9	14.3	5.3	6.3			
8	8.1	9.6			11.9	14.2	4.6	5.6			
9	7.1	8.7					4.4	5.4			
10	6.9	8.2					4.0	5.1			

Table 4d. Observed (obs.) and relative (rel.) survival of patients with GI cancer by ICD-10 classification for period 1998-2012 (N=36,645).




Figure 4e. Relative survival of patients with GI cancer by extent of disease. For 43,713 of 49,795 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 35,868 cases an evaluable classification was established. The grey line represents the subgroup of 13,927 patients with missing values regarding extent of disease (28.0% of 49,795 patients, the percent values of all other categories are related to n=35,868).

	Extent of disease											
	Loc	cal	Regi	onal	Distant		NA/NOS					
	n=14	,672	n=9,	529	n=11	,667	n=13	,927				
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %				
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0				
1	89.8	93.0	79.6	82.2	38.2	39.4	65.6	68.6				
2	83.8	89.7	63.9	68.0	19.6	20.8	54.1	58.8				
3	78.3	86.6	53.8	59.0	11.9	12.9	47.7	53.8				
4	73.4	84.0	47.2	53.3	8.6	9.6	42.9	50.1				
5	69.1	81.9	41.7	48.6	6.7	7.6	39.0	47.2				
6	64.4	79.0	38.3	46.0	5.5	6.4	36.2	45.3				
7	60.4	76.7	35.2	43.6	4.6	5.5	33.7	43.6				
8	56.8	74.7	33.0	42.1	4.1	4.9	31.3	42.0				
9	53.6	73.2	31.3	41.2	3.6	4.5	29.2	40.6				
10	50.9	71.9	29.9	40.6	3.3	4.3	27.4	39.5				

Table 4f. Observed (obs.) and relative (rel.) survival of patients with GI cancer by extent of disease for period 1988-2012 (N=35,868).




Figure 4g. Conditional relative 5-year survival of patients with GI cancer by extent of disease. For 43,713 of 49,795 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 35,868 cases an evaluable classification was established. The grey line represents the subgroup of 13,927 patients with missing values regarding extent of disease (28.0% of 49,795 patients, the percent values of all other categories are related to n=35,868).

Extent of disease												
	Loc	al	Regio	onal	Dist	ant	NA/N	IOS				
		Cond. surv. %		Cond. surv. %		Cond. surv. %		Cond. surv. %				
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs				
0	14,672	81.9	9,529	48.6	11,667	7.6	13,927	47.2				
1	12,565	85.5	7,214	56.2	4,123	16.3	8,605	66.4				
2	10,920	86.6	5,343	64.8	1,918	26.6	6,570	75.2				
3	9,407	87.8	4,063	72.6	1,025	38.5	5,343	79.6				
4	8,005	89.2	3,206	79.0	651	47.9	4,292	83.3				
5	6,784	90.5	2,510	85.7	435	56.8	3,476	86.5				
6	5,712	92.5	2,060	89.3	313	63.8	2,827	88.6				
7	4,975	93.7	1,734	92.7	222	68.8	2,358	88.9				
8	4,301	94.6	1,492	92.3	169	70.0	1,959	90.0				
9	3,747	93.7	1,282	91.9	127	71.7	1,629	89.9				
10	3,205	93.8	1,086	92.7	106	76.7	1,351	90.3				

Table 4h. Conditional relative 5-year survival of patients with GI cancer by extent of disease for period 1988-2012 (N=35,868).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4e). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 87.8% (n=9,407).




Figure 5a. Observed post-progression survival of 18,481 patients with GI cancer diagnosed between 1988 and 2012 (incl. M1). These 18,481 patients with documented progression events during their course of disease represent 37.1% of the totally 49,795 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=6,751, 13.6%). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

		Type of progr	ession	
	All types	Distant metastasis	Locoregional progress	NOS
	n=18,481	n=16,094	n=3,333	n=1,248
Months	%	%	%	%
0	100.0	100.0	100.0	100.0
12	43.6	41.7	51.5	39.0
24	25.6	23.3	33.2	26.2
36	16.8	14.6	23.1	18.8
48	12.5	10.6	17.6	15.8
60	10.1	8.3	14.6	14.0

Table 5b. Observed post-progression survival of patients with GI cancer for period 1988-2012 (N=18,481).

Shortcuts

AS Assembled survival chart (observed, expected, relative)

CS Conditional survival

DCO Death certificate only. The death certificate provides the only notification to the registry.

MCR Munich Cancer Registry, Germany (Tumorregister München)

NA Not available

NCI National Cancer Institute, USA

NOS Not otherwise specified

OS Observed/overall survival (Kaplan-Meier estimate)

PPS Post-progression survival

RS Relative Survival. Ratio of observed and expected survival (derived from the normal population)

SEER Surveillance, Epidemiology, and End Results, USA

TTP Time to progression

Date of entry: Date of diagnosis

Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified

recurrence

First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate).

First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where

applicable ("reverse" Kaplan-Meier estimate).

UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C15-C26: GI cancer [Internet]. 2014 [updated 2014 Mar 25; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C1526E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tb	ol.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	2
2a	Survival by gender (chart)	3
2b	Survival by gender (table)	3
3a	Relative survival by age category (chart)	4
3b	Observed survival by age category (chart)	4
3c	Survival by age category (table)	5
4a	Relative survival by ICD-10 classification 1988+ (chart)	5
4b	Survival by ICD-10 classification 1988+ (table)	6
4c	Relative survival by ICD-10 classification 1998+ (chart)	7
4d	Survival by ICD-10 classification 1998+ (table)	7
4e	Relative survival by extent of disease (chart)	8
4f	Survival by extent of disease (table)	8
4g	Conditional survival by extent of disease (chart)	9
4h	Conditional survival by extent of disease (table)	9
5a	Observed post-progression survival (chart)	10
5b	Observed post-progression survival (table)	10